Clinical trials: Refractory Chronic Cough, active
Cough, Refractory Chronic Cough
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).
- Trial name
- CALM-2 (NCT05600777)
- Testing
- BLU-5937
- Where
- 242 sites in United States, Australia and 11 more
- Volunteers
- 997 people
- Sponsor
- Bellus Health Inc. - a GSK company
Chronic Cough (CC)
Investigating the Role of ATP Production by Airway Epithelium in Patients With Refractory and Unexplained Chronic Cough (RCC/UCC).
Chronic cough is a common troublesome symptom which has a global prevalence of approximately 10%, but with wide variations across continents.
- Trial name
- APEC (NCT06600646)
- Testing
- Bronchoscopy
- Where
- Canada
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- McMaster University
Refractory Chronic Cough
The Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With Refractory Chronic Cough (RCC)
The purpose of this study is to evaluate the efficacy and safety of Nalbuphine ER Extended-release tablets for the treatment of participants with RCC.
- Trial name
- LAKE (NCT07671924)
- Testing
- NAL ER
- Where
- 21 sites in Canada, United Kingdom
- Volunteers
- 100 people
- Sponsor
- Trevi Therapeutics
Refractory Chronic Cough
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China Extension
This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).
- Trial name
- CALM-2 (NCT07650084)
- Testing
- BLU-5937
- Where
- 38 sites in China
- Volunteers
- 75 people
- Sponsor
- GlaxoSmithKline
Chronic Cough
Efficacy of Behavioral Therapy for Chronic Refractory Cough
Chronic cough is defined as cough persisting for more than eight weeks. It is a common clinical problem that significantly impairs patients' physical, psychological, and social quality of life.
- Trial name
- NCT07488598
- Testing
- Behavioral Therapy
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Assiut University
Refractory or Unexplained Chronic Cough
Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough
This is a phase 2b, randomized, double-blind, placebo-controlled study investigating the efficacy, safety, and tolerability of Taplucainium Inhalation Powder (NOC-110) once daily in adults with refractory or unexplained chronic…
- Trial name
- ASPIRE (NCT06504446)
- Testing
- NOC-110
- Where
- 106 sites in United States, Belgium and 4 more
- Volunteers
- 455 people
- Sponsor
- Nocion Therapeutics
Interstitial Lung Disease
Efficacy of Two Doses of Duloxetine & Amitriptyline in Interstitial Lung Disease-related Cough
This research study is evaluating the effectiveness of escalating doses of Amitriptyline and Duloxetine in reducing cough frequency in patients with interstitial lung disease (ILD)-related cough.
- Trial name
- MACS-2 (NCT05120934)
- Testing
- Amitriptyline 25 MG, Amitriptyline 50 MG, Duloxetine 30 MG
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Mayo Clinic
Upper-Airway Cough Syndrome
Laryngeal Cryotherapy for Refractory Neurogenic Cough
This study aims to evaluate the safety and efficacy of upper aerodigestive tract cryotherapy treatment in patients with refractory neurogenic cough in a prospective pilot study with a validated patient reported outcome measure
- Trial name
- NCT05665244
- Testing
- Laryngeal cryotherapy, Cryoprobe
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Texas Southwestern Medical Center
Refractory Chronic Cough, Unexplained Chronic Cough
Cough Management Wellness App for Refractory or Unexplained Chronic Cough
The goal of this single-cohort clinical trial is to learn whether a smartphone-based Cough Management (CM) program can reduce cough frequency and burden in adults (21-80 years) who have refractory or unexplained chronic cough.
- Conditions
- Refractory Chronic Cough, Unexplained Chronic Cough, Cough Hypersensitivity
- Trial name
- NCT07070895
- Testing
- Cough Management, CoughMonitor Suite
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Hyfe Inc
Idiopathic Pulmonary Fibrosis, Cough
Efficacy and Safety of ME-015 (Suplatast Tosilate) in Cough Related to Idiopathic Pulmonary Fibrosis (COSMIC-IPF)
Orally administered ME-015 (Suplatast Tosilate) has been available on the market as a prescription drug for allergy-related conditions in Japan since 1995 with a good safety and tolerability profile.
- Conditions
- Idiopathic Pulmonary Fibrosis, Cough, IPF, Fibrotic Lung Disease
- Trial name
- COSMIC-IPF (NCT05983471)
- Testing
- ME-015 (Suplatast Tosilate)
- Where
- 6 sites in India
- Volunteers
- 40 people
- Sponsor
- Melius Pharma AB
Refractory Chronic Cough
A Phase 2 Study of HW091077 in Participants With Refractory Chronic Cough Or Unexplained Chronic Cough (RCC/UCC).
This is a randomized, multicenter, double-blind, placebo-controlled, parallel-designed phase 2 clinical trial to evaluate the efficacy, safety and pharmacokinetic (PK) characteristics of HW091077 in Chinese adult subjects with…
- Trial name
- NCT07483489
- Testing
- HW091077
- Volunteers
- 180 people
- Sponsor
- Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.
Refractory Chronic Cough
Efficacy of Two Doses of Duloxetine and Amitriptyline in Subjects With Refractory Chronic Cough
This research study is evaluating the effectiveness of escalating doses of Amitriptyline and Duloxetine in reducing cough frequency in patients with refractory chronic cough (RCC)
- Trial name
- MACS-1 (NCT05110144)
- Testing
- Duloxetine 30 MG, Duloxetine 60 MG, Amitriptyline 25 MG
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mayo Clinic
Refractory Chronic Cough and Unexplained Chronic Cough
A Study to Investigate the Efficacy and Safety of SC0032, a Magnesium Salt Oral Spray, in Adults With Refractory or Unexplained Chronic Cough
This is a randomized placebo-controlled, parallel-arm study to determine the safety and efficacy of SC0032 in participants with RCC
- Trial name
- SensoryCloud (NCT07690059)
- Testing
- SC0032
- Where
- 3 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- Sensory Cloud, Inc.
Chronic Cough
The Real-world Treatment Satisfaction by Gefapixiant in RCC
Chronic cough has a high global prevalence and it is refractory to such treatments by approximately 20% of patients. Gafapixant is a P2X3 receptor antagonist that has demonstrated the reduction of cough in patients with…
- Trial name
- NCT06542484
- Testing
- Gefapixant Citrate
- Where
- 2 sites in Japan
- Volunteers
- 63 people
- Sponsor
- Nagoya City University
Chronic Cough (CC), Refractory Chronic Cough
Mechanisms of Change in Behavioral Cough Suppression Therapy for Refractory Chronic Cough
This study is testing new ways to help people who have chronic cough that has not improved with typical treatments. One approach is called behavioral cough suppression (BCS) therapy, which teaches people techniques to stop…
- Conditions
- Chronic Cough (CC), Refractory Chronic Cough, Unexplained Chronic Cough
- Trial name
- CoughLESS (NCT06960759)
- Testing
- BCS+inactive, BCS+active
- Where
- 3 sites in United States
- Volunteers
- 135 people
- Sponsor
- University of Montana
Cough, Refractory Chronic Cough
A 2x2 Factorial, Randomized, Open-label Trial to Evaluate Neuromodulators and Cough Control Therapy in Patients With Refractory or Unexplained Chronic Cough
The FORTITUDE trial will provide head-to-head evidence on the benefits and harms of two commonly prescribed neuromodulators (low-dose morphine and pregabalin), the effectiveness of a virtual cough control therapy, exploratory…
- Conditions
- Cough, Refractory Chronic Cough, Unexplained Chronic Cough, Cough Hypersensitivity Syndrome
- Trial name
- FORTITUDE (NCT07288528)
- Testing
- Morphine Sulphate, Morphine Sulphate + Cough Control Therapy, Pregabalin
- Where
- 5 sites in Canada
- Volunteers
- 124 people
- Sponsor
- McMaster University